Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jupiter Neurosciences, Inc. filings document a clinical-stage pharmaceutical issuer with common stock listed on the Nasdaq Capital Market and a business built around the JOTROL™ resveratrol platform and Nugevia™ products. Material-event reports cover standby equity purchase and registration-rights agreements, convertible promissory notes, amendments to installment provisions, and Nasdaq continued-listing notices.
Proxy materials disclose annual meeting matters, board governance and stockholder voting procedures. Rule 12b-25 notices document delayed periodic reports for annual and quarterly filings, while capital-structure disclosures address common stock, potential share issuances and related financing limitations.
Jupiter Neurosciences, Inc. entered a non-binding term sheet to acquire exclusive, perpetual U.S. rights to ALA-002, a next-generation MDMA formulation, from PharmAla Biotech. The term sheet calls for $3,333,333 upfront consideration ($1,500,000 cash and $1,833,333 in equity), a $600,000 escrow deposit, development and commercialization milestones, and a perpetual 3% royalty on U.S. net sales. The agreement is non-binding, contemplates definitive documentation within 90 days, includes a 90-day exclusivity/no-shop period, and conditions closing on due diligence, customary approvals, and any required shareholder or Nasdaq approvals.
Jupiter Neurosciences has executed a non-binding term sheet with PharmAla Biotech for a potential licensing deal giving Jupiter exclusive, perpetual U.S. rights to ALA-002, a next-generation MDMA formulation. The proposed structure includes an upfront $3.33 million payment split between cash and Jupiter equity, with $600,000 placed into escrow.
The term sheet outlines up to roughly $100 million in additional development and commercialization milestones plus a 3% royalty on U.S. net sales after all sales milestones are met. PharmAla has granted a 90-day exclusivity period, and the parties aim to sign definitive agreements within 90 days, though neither is obligated to close until binding contracts are executed.
If completed, the deal would add ALA-002, an FDA-recognized Novel Chemical Entity designed to improve MDMA cardiovascular safety and reduce abuse liability, to Jupiter’s CNS pipeline alongside its JOTROL and Nugevia programs.
Jupiter Neurosciences, Inc. files a prospectus supplement to its Form S-1 incorporating its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, updating the registration materials and attaching the unaudited 10-Q.
The 10-Q shows 36,281,252 shares outstanding as of May 14, 2026, $2,362,749 in cash at March 31, 2026, a net loss of $2,061,958 for the three months ended March 31, 2026, and an accumulated deficit of $36,728,984. Management discloses substantial doubt about going concern and describes a Standby Equity Purchase Agreement with Yorkville (up to $20.0M) and related convertible notes.
Jupiter Neurosciences, Inc. reported a first‑quarter 2026 net loss of $2,061,958 on $18,652 of product revenue, reflecting early commercialization of its Nugevia supplement line alongside ongoing R&D spending. Cash was $2,362,749 at March 31, 2026, against total liabilities of $6,732,041 and a stockholders’ deficit of $2,783,457, including an accumulated deficit of $36,728,984.
The company continues to fund operations through equity and convertible debt, notably a Standby Equity Purchase Agreement for up to $20.0 million of common stock and $6.0 million of related convertible notes, which had a fair value of $4,824,411 and principal of $5,527,625 outstanding. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes Nasdaq notifications for non‑compliance with minimum bid price and market value listing requirements, while advancing its JOTROL™ CNS drug pipeline and preparing a Phase IIa Parkinson’s trial.
Jupiter Neurosciences, Inc. files a prospectus supplement to its Form S-1 prospectus and attaches its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company discloses Nasdaq listing symbol JUNS, a closing share price of $0.3440 on May 7, 2026, and 36,281,252 shares of common stock issued and outstanding as of March 31, 2026. The 10-K describes Jupiter’s clinical-stage platform JOTROL™, its consumer Nugevia product line, an FDA-cleared IND for a Phase IIa Parkinson’s study (final IND approval in November 2025) expected to begin dosing in Q2 2026 with initial results anticipated about 12 months after first dosing. The 10-K highlights substantial financing needs, auditor explanatory going-concern language, patent coverage through 2036, Asian business-development agreements, and material risk factors affecting operations and liquidity.
Jupiter Neurosciences, Inc. filed a shelf registration on Form S-3 to offer, from time to time, up to $100,000,000 of common stock, preferred stock, debt securities, warrants, rights and/or units. The shelf permits multiple offerings under prospectus supplements describing specific terms and sale methods.
The company reported 36,281,252 shares of common stock issued and outstanding as of March 31, 2026, a public float of $13,632,945 based on 22,608,533 non-affiliate shares at $0.603 per share as of February 15, 2026, and a last reported sale price of $0.3940 on April 14, 2026. The prospectus states net proceeds will be used for general corporate purposes, including clinical trials and R&D.
Jupiter Neurosciences, Inc. files its annual report describing a clinical-stage CNS drug pipeline built around its proprietary resveratrol formulation JOTROL™ and a new consumer wellness brand, Nugevia. The company is advancing a Phase IIa Parkinson’s trial and planning additional studies in mild cognitive impairment, Alzheimer’s disease and rare disorders such as MPS I and MELAS.
Jupiter raised $11 million in December 2024 via a Nasdaq-listed public offering and is pursuing Asian partnerships and out-licensing to support development. However, it has generated minimal product revenue to date, carries indebtedness, requires substantial additional capital, and discloses that management and auditors see substantial doubt about its ability to continue as a going concern.
Jupiter Neurosciences, Inc. reported that Nasdaq has notified the company it is out of compliance with two continued listing standards for the Nasdaq Capital Market. The company’s common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days through February 25, 2026, and its market value of listed securities was below the required $35 million for the 30 consecutive business days ended February 26, 2026.
The company has until August 25, 2026 to regain compliance with each requirement, generally by maintaining a bid price of at least $1.00 and a market value of listed securities of at least $35 million for a minimum of 10 consecutive business days. If it fails to do so, its common stock may be subject to delisting, though the company could seek additional time or appeal. The company is monitoring its stock price and market value and may consider actions such as a reverse stock split.